

GHIT Fund Target Research Platform (TRP) Request for Proposals

Reference Number: GHIT-RFP-TRP-2025-002

Table of Contents

1. GHIT Fund Background.....	2
2. Funding Opportunity	2
3. Eligibility	3
4. Project Scopes	4
4.1 Project Scope for Standard TRP Award.....	4
4.2. Project Scope for Strategic Innovation and Market Assessment Award.....	6
4.3. Project Scope for R&D Accelerator Award	8
5. Partnership Roles.....	9
5.1 Roles and Responsibilities of the Designated Development Partner	9
5.2 Roles and Responsibilities of the Collaboration Partners	9
6. Applicant Instructions.....	10
7. Full Proposal Evaluation.....	11
7.1. Preliminary Examination.....	11
7.2. Technical Evaluation.....	11
7.3. Budget evaluation, organizational credit check.....	12
7.4. Award Administration and Conditions.....	12
7.5. Access Policy	13
7.6. Disclaimer	13
8. Key RFP Milestone Dates	13
9. Inquiries.....	14

1. GHIT Fund Background

With over a billion people in the world suffering from infectious diseases, especially in low-income countries (LICs) and lower-middle-income countries (LMICs), there is a need for new low-cost, high-impact health technologies. Responses to this need in recent years have led to the development of new products, mostly as a result of partnerships between pharmaceutical companies, academia and research institutions, and Product Development Partnerships (PDPs). These partnerships have proved to be an effective method for developing impactful global health technologies.

The Global Health Innovative Technology Fund (GHIT Fund) is a non-profit organization focused on promoting the discovery and development of new health technologies, including drugs, vaccines and diagnostics for infectious diseases prevalent in developing countries. The first fund of its kind in Japan, the GHIT Fund is supported by the Japanese Government, healthcare enterprises, the Wellcome Trust and the Gates Foundation. The GHIT Fund aims to advance Japan's wealth of health technology innovation for the discovery and development of new technologies for patients and populations affected by neglected infectious diseases. To this end, the GHIT Fund will catalyze R&D partnerships between Japanese and non-Japanese organizations and support these partnerships through GHIT Fund investments.

2. Funding Opportunity

The Target Research Platform (TRP) sits within the GHIT Fund's Discovery Investment focus area and consists of three Award types. This platform is intended to support the crucial, earlier phase of R&D discovery of new approaches, concepts, constructs and solutions to fight neglected infectious diseases.



The TRP is intentionally broad and offers support for innovative global health R&D as follows:

1. Standard TRP Award

The main award type under the TRP platform: this award aims to support early-stage research into novel technologies and approaches.

2. Strategic Innovation and Market Assessment Award (SIMA Award)

A This focusses on market assessment of a disease/technology market/landscape or market strategy analysis for a specific technology/product. Pre-discussion with the GHIT Fund is recommended before submitting an application.

3. R&D Accelerator Award

This aims to bridge activities for current/previous GHIT-funded projects by supporting supplemental activities.

3. Eligibility

- **Project:**

The proposal must align with the Project Scope, Disease Scope, Project Duration, and Budget of each Award as outlined in this document.

- **Partnership:**

Each proposal must have at least one Japanese organization and one non-Japanese organization

Notes:

- ✓ Whether the organization is Japanese or non-Japanese is defined by the location of its headquarters.
- ✓ A multinational group of companies will be considered as a single Japanese/non-Japanese organization.
- ✓ The following table presents examples of organization types.

Organization Types (examples)
<ul style="list-style-type: none">• Life science/healthcare companies• Academic institutions• Non-profit research organizations and foundations• Government research institutions• Product Development Partnerships (PDPs)

- **Organizational information:**

Each organization must submit a certified copy of its registration and financial statements (audited by an independent auditor) from the most recent 3 fiscal years.

In the case that the organization is less than 3 years old, the financial statements that are available at the time of the application to GHIT should be submitted.

4. Project Scopes

4.1 Project Scope for Standard TRP Award

Project Scope:	<p><u>Early-stage R&D project primarily originating from or materially involving Japanese science, technology and/or know-how</u></p> <ul style="list-style-type: none"> - Projects based on innovations originating outside Japan may still be eligible, provided the Japanese partner plays a central and indispensable role in advancing or refining the technology. - Projects where the Japanese partner's role is limited to minor tasks (e.g., generating supporting data or supplying control samples) are not eligible. - Proposals must include preliminary data or supporting evidence. Hypothesis-driven proposals without data will not be considered.
Disease Scope:	<p>The following diseases listed in the GHIT Fund <i>Intent to Apply</i> form:</p> <ul style="list-style-type: none"> - Malaria - Tuberculosis (TB) - Neglected Tropical Diseases (NTDs)* - Diseases with pandemic potential** - Diseases with public health emergency*** <p><i>*For NTDs, all WHO listed NTDs are eligible; however, please note that funding scope, including the type of intervention, is limited for the continuing GHIT Fund Product Development Platform once the TRP project is successfully completed.</i></p> <p><i>**For diseases with pandemic potential, we are particularly interested in proposals that are aligned with the WHO list of priority pathogens of epidemic and pandemic threat (https://www.who.int/teams/blueprint/who-r-and-d-blueprint-for-epidemics) excluding approaches which are specific only for COVID-19.</i></p> <p><i>***For diseases with public health emergency the justification must be provided as to why the target disease is considered to be one with public health emergency.</i></p> <p><i>Especially for vaccine research related to diseases with pandemic potential and public health emergency, applicants are strongly encouraged to seek funding from other agencies first.</i></p>
Project Duration:	Not to exceed two years
Budget:	max. JPY 100,000,000

The tables below provide examples of potentially eligible and ineligible project scopes for the Standard TRP Award. Please visit the [GHIT Fund Website](#) for examples of previously funded projects.

Scope for Drugs	
Examples of Eligible Projects	<ol style="list-style-type: none"> 1. Novel mechanisms of action, e.g., targeting critical host components essential for infection and disease with little or no toxic effect on the host 2. Conventional drug discovery approaches including; <ul style="list-style-type: none"> • Standard high-throughput screening against pathogens • Hybrid-drug approaches/strategies • Target-based drug development for potential novel biological targets or pathways

	<ol style="list-style-type: none"> 3. Novel assay technologies that allow screening for therapeutics against pathogens within GHIT's scope 4. Pharmacogenomics studies to understand the drug metabolism and disposition in malaria, TB, NTDs and disease with pandemic potential 5. Innovative drug delivery modality/methods such as lipid nano-particles, nucleic acid delivery system and use of microneedle patches etc. 6. Repurposing of existing health technologies (e.g. approved drug and platform technologies) for use in new indications (malaria, TB and NTDs) and diseases with pandemic potential
Ineligible	<ol style="list-style-type: none"> 1. Mathematical analysis, modeling and prediction of the evolution, spread and fitness of resistant mutants during drug treatment, both within a single individual and in an epidemiological context 2. Project that specifically targets pathogens that cause diseases not listed in this RFP 3. Basic studies of pathogens or human biology 4. Community-based interventions aimed at improving adherence to drug treatment regimens
Scope for Vaccines	
Examples of Eligible Projects	<ol style="list-style-type: none"> 1. Novel vaccine concepts, targets and constructs inspired by new observations or understanding about the nature of the targeted organism or human response to that organism 2. New vaccine constructs that target specific tissue or cell types for appropriate induction of local and systemic immunity 3. Use of cutting-edge technologies to enhance vaccine development, such as utilizing synthetic biology or novel genetic engineering strategies to design and produce next-generation immunogens 4. New interventions targeting hard-to-reach human and vector populations, e.g., vaccines for malaria parasites that remain underserved by current tools, such as <i>P. vivax</i>, <i>P. malariae</i>, <i>P. ovale</i> and <i>P. knowlesi</i>.
Ineligible	<ol style="list-style-type: none"> 1. Development of dengue vaccines 2. Identification of malaria or TB antigens without demonstrable improvement in efficacy or efficiency 3. Projects targeting molecular pathways already targeted by antigens or adjuvants currently in late-stage clinical development or in market 4. Approaches that represent incremental improvements to conventional solutions 5. Basic studies of pathogens or human biology
Scope for Diagnostics	
Examples of Eligible Projects	<ol style="list-style-type: none"> 1. New and improved approaches to traditional immune and molecular assay methods 2. Biochemical amplification or analysis of non-invasive samples such as urine, saliva, sweat or other excreted fluids 3. Development of cost-effective diagnostics by utilizing or repurposing off-patent/discontinued/novel technologies that are anticipated to encounter minimal regulatory and safety barriers 4. Innovative design for customizable multiplexing which can be delivered to endemic regions 5. Customizable multiplex diagnostics designed for deployment in endemic regions 6. Repurposing of approved medical devices, diagnostic tests or platform diagnostic technologies for uses in malaria, TB, NTDs, or diseases with pandemic potential
Ineligible	<ol style="list-style-type: none"> 1. Technical improvements or enhancements of a diagnostic with little or no apparent relevance to or impact on a global health problem 2. Improvements focused solely on microfluidic design, signal detection, or other platform elements without a clear pathway to application in GHIT priority diseases

4.2 Project Scope for Strategic Innovation and Market Assessment Award

Project Scope:	<ul style="list-style-type: none"> • Disease/market landscape and/or technology landscape assessment • Market strategy analysis for a specific technology/product • Development and publication of a Target Product Profile (TPP)
Disease Scope:	<p>Following diseases listed in the GHIT Fund <i>Intent to Apply</i> form; however, please refer to the table for Scope of Drugs, Vaccines and Diagnostics. Please contact the GHIT Fund for more details:</p> <ul style="list-style-type: none"> - Malaria - Tuberculosis (TB) - Neglected Tropical Diseases (NTDs)* - Disease with pandemic potential** - Disease with public health emergency*** <p><i>*For NTDs, all WHO listed NTDs are eligible; however, please note that funding scope, including the type of intervention, is limited for the continuing GHIT Fund Product Development Platform once the TRP project is successfully completed.</i></p> <p><i>**For diseases with pandemic potential, we are particularly interested in proposals that are aligned with the WHO list of priority pathogens of epidemic and pandemic threat (https://www.who.int/teams/blueprint/who-r-and-d-blueprint-for-epidemics) excluding approaches which are specific only for COVID-19.</i></p> <p><i>***For diseases with public health emergency the justification must be provided as to why the target disease is considered to be one with public health emergency.</i></p>
Project Duration:	Not to exceed 6 months
Budget:	max. JPY 50,000,000
Additional Requirement:	The outcome of the analysis or assessment will be published on the GHIT Fund website.

Scope for Drugs	
Examples of Eligible Projects	<ol style="list-style-type: none"> 1. Disease/market landscape and technology landscape analysis to identify unmet and/or priority needs during concept development – aimed at enabling future technology development where Japanese technology/know-how can play a significant role in addressing <u>malaria, TB, NTDs, and diseases with public health emergency or pandemic potential.</u> Applicants may choose to focus on one or more of the following therapeutic modalities (not limited to this list): <ul style="list-style-type: none"> ✓ Small and medium molecule drug discovery ✓ Antibody therapeutics ✓ Nucleic acid-based drugs ✓ Drug delivery systems (DDS) ✓ Phage therapy ✓ Synthetic phage-based therapeutics ✓ Exosome-based drug discovery ✓ Targeted protein degradation (TPD) 2. Market strategy analysis of a specific technology/product to assess: <ul style="list-style-type: none"> • Applicability to address unmet and/or priority needs in comparison to similar modality and/or use cases • Applicability in LMICs • Manufacturing strategy and capabilities • Regulatory strategy as part of concept development. 3. Research to develop and publish a TPP for disease and intervention/modality where no TPP exists or where an update is needed
Ineligible	<ol style="list-style-type: none"> 1. Disease/market landscape and technology landscape through a simple desktop and/or AI search.
Scope for Vaccines	
Examples of Eligible Projects	<ol style="list-style-type: none"> 1. Market strategy analysis of a specific technology/product to assess: <ul style="list-style-type: none"> • Applicability to address unmet and/or priority needs in comparison to similar modality and/or use cases • Applicability in LMICs • Manufacturing strategy and capabilities • Regulatory strategy as part of concept development. 2. Research to develop and publish a TPP or Preferred Product Characteristics (PPC) for disease and intervention/modality where no TPP or PPC exists or where an update is needed.
Ineligible	<ol style="list-style-type: none"> 1. Disease/market landscape and technology landscape work to address unmet and/or priority needs as a part of concept development, eventually leading to technology development, and to identify technologies/platforms/solutions, etc., for which Japan can significantly contribute to fight against malaria, TB, NTDs and disease with pandemic potential. 2. Disease/market landscape and technology landscape through a simple desktop and/or AI search.
Scope for Diagnostics	
Examples of Eligible Projects	<ol style="list-style-type: none"> 1. Market landscape work of non-invasive diagnosis and/or medical device to understand the unmet and/or priority needs and/or applicability in LMICs setting as part of concept development. 2. Research to develop and publish a TPP for disease and intervention/modality where no TPP exists or where an update is needed.

Ineligible	<ol style="list-style-type: none"> 1. Disease/market landscape and technology landscape work to address unmet and/or priority needs as a part of concept development, eventually leading to technology development, and to identify technologies/platforms/solutions, etc., for which Japan can significantly contribute to fight against malaria, TB, NTDs and disease with pandemic potential. 2. Disease/market landscape and technology landscape through a simple desktop and/or AI search.
------------	--

4.3 Project Scope for R&D Accelerator Award

Project Scope:	<u>Supports bridging activities that preferentially support advance current or previously GHIT-funded projects toward the next stage of product development.</u>
Disease Scope:	<p>Following diseases listed in the GHIT Fund <i>Intent to Apply</i> form. Please contact the GHIT Fund for more details:</p> <ul style="list-style-type: none"> - Malaria - Tuberculosis (TB) - Neglected Tropical Diseases (NTDs)* - Diseases with pandemic potential** - Diseases with public health emergency <p><i>*For NTDs, all WHO listed NTDs are eligible; however, please note that funding scope, including the type of intervention, is limited for the continuing GHIT Fund Product Development Platform once the TRP project is successfully completed.</i></p> <p><i>**Limited funding available for creating prototypes of diagnostics addressing public health emergency or pandemic potential.</i></p> <p><i>***For diseases with pandemic potential, we are particularly interested in proposals that are aligned with the WHO list of priority pathogens of epidemic and pandemic threat (https://www.who.int/teams/blueprint/who-r-and-d-blueprint-for-epidemics) excluding approaches which are specific only for COVID-19.</i></p> <p><i>***For diseases with public health emergency the justification must be provided as to why the target disease is considered to be one with public health emergency.</i></p>
Project Duration:	Not to exceed 6 months
Budget:	max. JPY 20,000,000

Scope for Drugs/Vaccines/Diagnostics	
Examples of Eligible Projects	<ol style="list-style-type: none"> 1. Translational science and capacity building activities that support the advancement of GHIT-funded projects, such as <ul style="list-style-type: none"> ● Developing a product development plan ● Identifying a product development partner ● Engaging with regulatory agencies for consultation
Ineligible	<ol style="list-style-type: none"> 1. Activities for projects that the GHIT Fund has not awarded previously.

5. Partnership Roles

Partner organizations in a partnership are called Collaboration Partners (CPs). The partnership must nominate one partner as a Designated Development Partner (DDP), who has the primary responsibility for the project's execution, while CPs support the project through compliance with their respective obligations. The roles and responsibilities of the DDP and the CPs are summarized below. Please note that DDP must comply with the roles of DDP as well as the roles of CP.

5.1 Roles and Responsibilities of the Designated Development Partner

From Proposal submission to proposal evaluation

- Act as primary point of contact with the GHIT Fund
- Coordinates and submits proposals and relevant documents on behalf of all the CPs

After Award

- Primary Representative: Main liaison between the CPs and the GHIT Fund.
- Funding Recipient: Receives the funding from the GHIT Fund and is responsible for distributing funding to other CPs.
- Project Oversight: Ensures overall project performance and monitors each CP's work and compliance with the terms of the Investment Agreement.
- Investment Management: Manages the use of the investment in accordance with the approved budget; oversees audits, financial reporting, and related requests.
- Reporting: Oversees and submits the Progress Reports, including itemized expenditure reports, and ensures proper documentation and compliance with the GHIT Fund's guidelines.
- Dual Role as CP: In addition to the roles and responsibilities unique to the DDP, the DDP must adhere to the roles and responsibilities of a CP to the extent it does not interfere or conflict with its role as a DDP.

5.2 Roles and Responsibilities of the Collaboration Partners

From Proposal submission to proposal evaluation

- Provides necessary input and information to the DDP for the proposal preparation

After Award

- Project Participation and Obligations: Each CP delivers their assigned portion of the project and complies with all the terms of the Investment Agreement.
- Collaboration Agreement: Enters into a separate contractual relationship with the other CPs, subject to the GHIT Fund's approval, to formalize their collaboration.
- Approval of Subcontractors: CPs must adhere to the limitation on the hiring of subcontractors, under which CPs may not hire subcontractors without the GHIT Fund's approval unless the subcontractors have been previously identified in the project proposal.
- Audit and Financial Compliance: Each CP maintains accurate financial records and provides access to all relevant documentation; subject to potential audits by both the DDP and the GHIT Fund.
- Legal and Ethical Compliance: CPs must comply and adhere to all applicable laws and ethical standards, including those regarding anti-corruption, anti-terrorism.
- Legal Responsibility: CPs must indemnify the GHIT Fund and its affiliates from and against any legal actions or liabilities arising out of the Investment or the project, except to the extent such action or liability is attributable to any gross negligence or willful misconduct by the GHIT Fund.

6. Applicant Instructions

Editorial Manager®

To receive and manage applications, the GHIT Fund uses **Editorial Manager® for Target Research Platform** (https://www.editorialmanager.com/ghitfund_trp), an online document submission system dedicated for this program. Please note that the *Intent to Apply* documents or Proposals that are not submitted through the above-mentioned system will not be accepted.

Language: All correspondence and documents relating to this RFP shall be written in English.

Associated Expenses: The applicant shall bear all costs associated with the preparation and submission of the proposal, including costs associated with proposal presentation and contract negotiation.

Step 1 - Intent to Apply

Interested applicants must complete the *Intent to Apply* form (**GHIT-RFP-TRP-2025-002_IntentToApply.docx**) and submit the form to the GHIT Fund via Editorial Manager® no later than:

10:00 am JST on July 9, 2025

The *Intent to Apply* form is available on the GHIT Fund website:

<https://www.ghitfund.org/applyforfunding/trp/en>.

- *Intent to Apply* form must be reviewed and approved by all Collaboration Partners prior to submission.
- Any application not using the designated *Intent to Apply* form for this RFP will not be accepted.
- Please do not attach any documents to the *Intent to Apply* form.
- When submitting your *Intent to Apply* form on the Editorial Manager®, please list all the Collaboration Partners participating in the project; the name and details (including e-mail address) of at least one representative from each organization must be indicated.
- After submitting the *Intent to Apply* form, you will receive a confirmation e-mail.

The GHIT Fund Management Team will then perform an initial partnership and scope eligibility assessment. **Only eligible applicants will be invited to submit the full proposal and receive access to the proposal template.**

Eligibility assessment will be conducted upon receipt of the *Intent to Apply* form. Applicants are encouraged to submit the *Intent to Apply* form well in advance of the full proposal submission deadline to secure sufficient time to prepare a full proposal.

Step 2 - Full Proposal Submission

Applicants invited to submit a full proposal are required to do so via Editorial Manager® no later than:

10:00 am JST on August 7, 2025

- Proposals must be reviewed and approved by all Collaboration Partners prior to submission.
- The *Collaboration Partners' Approval* form (**ProjectID-CollaborationPartnerApproval.docx**) must be signed by all Collaboration Partners, and a PDF copy must be submitted along with other proposal documents.
- Applicants who successfully submit their proposal documents will receive a confirmation e-mail.
- Proposals may not be modified after the submission due date.

- Additional documents (including additional data and/or supporting documents) cannot be accepted after the deadline. The GHIT Fund may, at its own discretion, extend the closing date by notifying applicants.
- Proposals received after the closing date for submission without prior agreement will be ineligible but may be resubmitted in future RFPs.

7. Full Proposal Evaluation

The following evaluations will be conducted for the submitted Full Proposal.

7.1 Preliminary Examination

TRP proposals will initially be examined to determine or evaluate:

- whether the partnership meets GHIT Fund eligibility criteria
- whether the project primarily originates from or materially involve Japanese science, technology and/or know-how
- whether the project objectives are aligned with the RFP-specified scope
- whether the proposal is complete and addresses all required contents
- that the overall budget does not exceed the budget specified in the Project Scope section.
- that the required organizational documents have been submitted for each organization.

Applicants will be notified by e-mail of their proposal's readiness for technical evaluation. The GHIT Fund Management Team may ask clarifying questions or request additional information, as needed, to qualify proposals for evaluation. Organizational information and financial statements will be reviewed during the Budget evaluation, organizational credit check step.

7.2 Technical Evaluation

All eligible proposals will be evaluated based on the following criteria:

- Scientific and technical merit (e.g., sound approach and methodology, level of innovation, overall quality and comprehensiveness)
- Potential impact (e.g., how it will address a global health priority)
- Partnership (e.g., collaboration capabilities and expertise, project history)
- Project management (e.g., performance and risk management, decision-making process)

Evaluation Process:

- Eligible proposals will initially be reviewed by three External Reviewers (ER), typically including Japanese and non-Japanese reviewers.
- The aggregated ER review results and the proposals will then be shared with the GHIT Fund Selection Committee (SC) for evaluation.
- After the evaluation, the GHIT Fund will invite selected proposals for an interview with the SC. **Selected proposals will be notified of the SC interview invitation approximately one month prior to the scheduled interview date and time.**
- ER and SC members have signed non-disclosure agreements with the GHIT Fund prior to the evaluation.
- Following the interview, the SC will make final funding decisions with appropriate conditions for the Standard TRP Award and report the decisions to the GHIT Board.
- For proposals applying for Strategic Innovation and Market Assessment Award and R&D Accelerator Award, where limited funding opportunity is available, eligible proposals are subject to an internal review involving the SC, GHIT Fund Management Team, and other appropriate reviewers.
- Evaluation procedures and their format may be adjusted due to unforeseen circumstances.

7.3 Budget evaluation, organizational credit check

All proposals that pass the other requirements of preliminary evaluation will also be subject to evaluation of the budget and an organizational credit check (so called Due Diligence) in detail according to the following criteria:

- Detailed budget for each category provided by each Collaboration Partner is reasonable and appropriate to address the project's R&D activities to be conducted by each Collaboration Partner by phase/activity/milestone.*
- Results of the organizational compliance and credit check reveal no significant issues or concerns.**

Depending on the outcome of the organizational credit check, conditions may apply for the funding from the GHIT Fund (milestone-based payments, deliverable-based payment and any other installment payments etc.) or may be considered not fundable.

**A detailed budget for each category outlining the expenditures for the project to be conducted by each Collaboration Partner should be outlined in the budget sheet as well as the budget section of the Project Full Proposal.*

***Organizational status and adherence to relevant compliance policies should be outlined in the relevant part of the Project Full Proposal.*

7.4 Award Administration and Conditions

Notification of Results

- After GHIT Board approval, the GHIT Fund will notify applicants of the award decision by e-mail.
- Please note that the GHIT Fund is not able to provide feedback to applicants receiving a non-award decision.

Agreements

- If the proposal is selected and the applicant receives an award notification, all partners are required to sign an Investment Agreement with the GHIT Fund and put in place a contractual agreement among the Collaboration Partners, which clearly defines the roles and responsibilities of all Collaboration Partners within two weeks to one month from the award notification.
- The Investment Agreement template will be shared with the applicants who are considered eligible to submit the Proposal.
- The award may be revoked or considered void if any of the conditions are not met.
- Please note that (1) the GHIT Fund may update the Investment Agreement template from time to time, and (2) while the GHIT Fund is open to discuss the terms of the Investment Agreement on a case-by-case basis, the template represents the GHIT Fund's positions generally except in certain circumstances where the Collaboration Partners can present reasonable grounds for exceptions or modifications (such as undue burdens). The GHIT Fund has the right to terminate the Investment Agreement if:
 - The partnership disbands prior to satisfying its investment project obligations.
 - The progress of work is such that the obligations undertaken by the partnership will not be fulfilled.
 - The partnership fails to meet the milestones or goals specified in the Investment Agreement.

7.5 Access Policy

The applicants are required to agree to the Access Policy of the GHIT Fund to ensure that GHIT's objectives of providing equitable and affordable access are met.

Details about the GHIT Access Policy can be found here:

<https://www.ghitfund.org/applyforfunding/accesspolicy/en>.

7.6 Disclaimer

The GHIT Fund Management Team does not have any influence, authority or decision-making power with respect to: (i) review and evaluation, (ii) funding recommendations and (iii) funding decisions of submitted proposals by the ER, SC and the Board of Directors. In addition, submission of the *Intent to Apply* form and proposal documents to the GHIT Fund and participation by proposal partners in the SC interview do not guarantee an automatic funding approval for your proposal.

8. Key RFP Milestone Dates

Award type	3.1 Standard TRP Award	3.2 Strategic Innovation and Market Assessment Award 3.3 R&D Accelerator Award
RFP Release	June 12, 2025	
Intent to Apply Due	No later than 10:00 am JST on July 9, 2025 *Applicants are encouraged to submit the ITA well in advance of the Full Proposal submission deadline shown below to secure sufficient time to prepare full proposal. Submit via Editorial Manager® for Target Research Platform (https://www.editorialmanager.com/ghitfund_trp/)	
Full Proposal Due	No later than 10:00 am JST on August 7, 2025 Submit via Editorial Manager® for Target Research Platform (https://www.editorialmanager.com/ghitfund_trp/)	
Proposal Evaluation and Interview Processes	August 2025 - February 2026	August 2025 - October 2025
Award Notification to All Applicants	February 2026	October 2025
Investment Agreement Fully Executed (Awarded Proposals)	March 2026	October 2025 or later

(The schedule is subject to change due to unforeseen circumstances.)

For proposals addressing diseases with Pandemic Potentials and diseases with public health emergency, Proposals may be submitted outside the above-mentioned timeline, please contact the GHIT Fund for more details.

9. Inquiries

For any inquiries, please contact RFPresponse@ghitfund.org (please use the e-mail subject line: **GHIT-RFP-TRP-2025-002_Questions**)

A Frequently Asked Questions (FAQ) page is available on the GHIT Fund website:
(<https://www.ghitfund.org/applyforfunding/investmentfaq/en>).

[End of Document]